| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma | 89 | 2023 | 1800 | 9.400 |
Why?
|
| Chordoma | 27 | 2023 | 347 | 5.500 |
Why?
|
| Spinal Neoplasms | 23 | 2022 | 703 | 3.820 |
Why?
|
| Soft Tissue Neoplasms | 30 | 2023 | 1158 | 3.790 |
Why?
|
| Retroperitoneal Neoplasms | 20 | 2021 | 333 | 3.570 |
Why?
|
| Extremities | 25 | 2018 | 867 | 2.650 |
Why?
|
| Sacrum | 13 | 2023 | 275 | 2.200 |
Why?
|
| Radiotherapy Dosage | 52 | 2021 | 2897 | 2.040 |
Why?
|
| Photons | 17 | 2019 | 589 | 1.970 |
Why?
|
| Bone Neoplasms | 22 | 2021 | 2527 | 1.820 |
Why?
|
| Radiation Oncology | 13 | 2021 | 563 | 1.760 |
Why?
|
| Radiotherapy, Conformal | 15 | 2020 | 548 | 1.670 |
Why?
|
| Radiotherapy | 13 | 2021 | 1500 | 1.440 |
Why?
|
| Osteosarcoma | 11 | 2019 | 896 | 1.270 |
Why?
|
| Tumor Burden | 15 | 2017 | 1892 | 1.130 |
Why?
|
| Radiotherapy, Adjuvant | 28 | 2021 | 1784 | 1.120 |
Why?
|
| Neoplasm Recurrence, Local | 39 | 2021 | 9278 | 1.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 19 | 2021 | 1655 | 1.040 |
Why?
|
| Chondrosarcoma | 8 | 2019 | 295 | 1.010 |
Why?
|
| Fibromatosis, Aggressive | 6 | 2019 | 126 | 0.950 |
Why?
|
| Neoadjuvant Therapy | 20 | 2021 | 2827 | 0.860 |
Why?
|
| Radiotherapy, Intensity-Modulated | 11 | 2020 | 801 | 0.850 |
Why?
|
| Cauda Equina | 1 | 2021 | 45 | 0.750 |
Why?
|
| Radiotherapy, High-Energy | 4 | 2018 | 228 | 0.690 |
Why?
|
| Abdominal Neoplasms | 3 | 2017 | 287 | 0.650 |
Why?
|
| Neoplasms, Second Primary | 6 | 2020 | 1052 | 0.640 |
Why?
|
| Spinal Cord Neoplasms | 3 | 2017 | 261 | 0.600 |
Why?
|
| Organs at Risk | 7 | 2020 | 359 | 0.590 |
Why?
|
| Brachytherapy | 9 | 2021 | 1223 | 0.590 |
Why?
|
| Chondrosarcoma, Mesenchymal | 1 | 2016 | 12 | 0.560 |
Why?
|
| Combined Modality Therapy | 44 | 2021 | 8519 | 0.520 |
Why?
|
| Negative-Pressure Wound Therapy | 3 | 2022 | 156 | 0.500 |
Why?
|
| Humans | 225 | 2023 | 761222 | 0.490 |
Why?
|
| Misonidazole | 1 | 2014 | 33 | 0.490 |
Why?
|
| Thoracic Vertebrae | 3 | 2015 | 612 | 0.480 |
Why?
|
| Radiation Injuries | 14 | 2016 | 1191 | 0.470 |
Why?
|
| Lumbar Vertebrae | 5 | 2023 | 1876 | 0.470 |
Why?
|
| Aged | 96 | 2021 | 169292 | 0.460 |
Why?
|
| Preoperative Care | 9 | 2021 | 2241 | 0.460 |
Why?
|
| Spine | 3 | 2017 | 1129 | 0.450 |
Why?
|
| Middle Aged | 111 | 2021 | 220858 | 0.440 |
Why?
|
| Skull Base Neoplasms | 2 | 2016 | 270 | 0.440 |
Why?
|
| Aged, 80 and over | 46 | 2021 | 58952 | 0.440 |
Why?
|
| Adult | 103 | 2021 | 221120 | 0.430 |
Why?
|
| Disease-Free Survival | 16 | 2018 | 6819 | 0.430 |
Why?
|
| Thoracic Neoplasms | 1 | 2014 | 268 | 0.410 |
Why?
|
| Histiocytoma, Malignant Fibrous | 3 | 2014 | 55 | 0.400 |
Why?
|
| Cell Hypoxia | 1 | 2014 | 656 | 0.400 |
Why?
|
| Neoplasms | 15 | 2020 | 22142 | 0.390 |
Why?
|
| Photochemotherapy | 11 | 1997 | 826 | 0.390 |
Why?
|
| Treatment Outcome | 50 | 2022 | 64681 | 0.390 |
Why?
|
| Patient Positioning | 2 | 2013 | 326 | 0.380 |
Why?
|
| Scattering, Radiation | 3 | 2017 | 490 | 0.380 |
Why?
|
| Medication Reconciliation | 1 | 2013 | 153 | 0.370 |
Why?
|
| Liposarcoma | 4 | 2016 | 289 | 0.360 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 17 | 2019 | 11733 | 0.360 |
Why?
|
| Retrospective Studies | 50 | 2022 | 80675 | 0.350 |
Why?
|
| Chemotherapy, Adjuvant | 15 | 2017 | 3512 | 0.340 |
Why?
|
| Radiation-Sensitizing Agents | 3 | 1998 | 349 | 0.340 |
Why?
|
| Head and Neck Neoplasms | 7 | 2014 | 2894 | 0.340 |
Why?
|
| Follow-Up Studies | 31 | 2019 | 39127 | 0.340 |
Why?
|
| Spinal Cord | 2 | 2016 | 1807 | 0.330 |
Why?
|
| Male | 124 | 2021 | 360703 | 0.330 |
Why?
|
| Adolescent | 45 | 2021 | 88300 | 0.330 |
Why?
|
| Female | 127 | 2021 | 392552 | 0.330 |
Why?
|
| Survival Rate | 26 | 2019 | 12728 | 0.320 |
Why?
|
| Relative Biological Effectiveness | 8 | 2017 | 311 | 0.320 |
Why?
|
| Young Adult | 33 | 2021 | 59222 | 0.320 |
Why?
|
| Medical History Taking | 1 | 2013 | 773 | 0.320 |
Why?
|
| Dose-Response Relationship, Radiation | 9 | 2019 | 880 | 0.310 |
Why?
|
| Tomography, X-Ray Computed | 17 | 2023 | 20588 | 0.300 |
Why?
|
| Cyclotrons | 1 | 2007 | 30 | 0.290 |
Why?
|
| Radiodermatitis | 3 | 2019 | 60 | 0.290 |
Why?
|
| Neoplasms, Radiation-Induced | 5 | 2019 | 549 | 0.290 |
Why?
|
| Hematoporphyrin Photoradiation | 5 | 1994 | 17 | 0.280 |
Why?
|
| Medical Records | 1 | 2013 | 1409 | 0.280 |
Why?
|
| Protons | 4 | 2022 | 1111 | 0.270 |
Why?
|
| Practice Guidelines as Topic | 7 | 2017 | 7400 | 0.270 |
Why?
|
| Kaplan-Meier Estimate | 12 | 2019 | 6486 | 0.270 |
Why?
|
| Neoplasm, Residual | 5 | 2014 | 1008 | 0.270 |
Why?
|
| Consensus | 8 | 2021 | 3134 | 0.260 |
Why?
|
| Cholangiocarcinoma | 3 | 2018 | 554 | 0.260 |
Why?
|
| Postoperative Care | 5 | 2021 | 1468 | 0.260 |
Why?
|
| Paranasal Sinus Neoplasms | 2 | 2016 | 242 | 0.260 |
Why?
|
| Isotretinoin | 2 | 1998 | 134 | 0.260 |
Why?
|
| Fractures, Spontaneous | 2 | 2019 | 231 | 0.260 |
Why?
|
| Fibrosarcoma | 2 | 2021 | 308 | 0.250 |
Why?
|
| Radiosurgery | 3 | 2020 | 1339 | 0.250 |
Why?
|
| Retreatment | 2 | 2021 | 598 | 0.250 |
Why?
|
| Dihematoporphyrin Ether | 4 | 1994 | 33 | 0.250 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 2684 | 0.240 |
Why?
|
| Nerve Sheath Neoplasms | 2 | 2019 | 170 | 0.240 |
Why?
|
| Physicians | 1 | 2023 | 4584 | 0.240 |
Why?
|
| Anus Neoplasms | 2 | 2019 | 330 | 0.230 |
Why?
|
| Neoplasm Staging | 17 | 2021 | 11119 | 0.230 |
Why?
|
| Liver Neoplasms | 5 | 2019 | 4310 | 0.230 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 2019 | 2293 | 0.230 |
Why?
|
| Enteritis | 1 | 2005 | 162 | 0.230 |
Why?
|
| Iridium Radioisotopes | 1 | 2003 | 26 | 0.230 |
Why?
|
| Fluorouracil | 5 | 2019 | 1642 | 0.220 |
Why?
|
| Limb Salvage | 3 | 2016 | 480 | 0.220 |
Why?
|
| Osteotomy | 1 | 2009 | 836 | 0.220 |
Why?
|
| Pancreatic Neoplasms | 7 | 2019 | 5366 | 0.210 |
Why?
|
| Feasibility Studies | 11 | 2019 | 5250 | 0.210 |
Why?
|
| Interferon-alpha | 2 | 1998 | 907 | 0.210 |
Why?
|
| Bandages | 2 | 2021 | 269 | 0.210 |
Why?
|
| Particle Accelerators | 2 | 2018 | 174 | 0.210 |
Why?
|
| Hemangiosarcoma | 2 | 2020 | 215 | 0.210 |
Why?
|
| Prognosis | 23 | 2021 | 29688 | 0.210 |
Why?
|
| Yttrium Radioisotopes | 1 | 2003 | 107 | 0.200 |
Why?
|
| Doxorubicin | 7 | 2012 | 2224 | 0.200 |
Why?
|
| Survival Analysis | 13 | 2019 | 10088 | 0.200 |
Why?
|
| Mesna | 4 | 2012 | 62 | 0.200 |
Why?
|
| Biopsy, Needle | 2 | 2006 | 1624 | 0.200 |
Why?
|
| Ifosfamide | 5 | 2012 | 232 | 0.190 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2015 | 2047 | 0.190 |
Why?
|
| Intraoperative Period | 4 | 2010 | 510 | 0.190 |
Why?
|
| Dura Mater | 1 | 2003 | 290 | 0.190 |
Why?
|
| Abdominal Wall | 2 | 2014 | 166 | 0.190 |
Why?
|
| Positron-Emission Tomography | 3 | 2020 | 6586 | 0.190 |
Why?
|
| Neurofibromatosis 1 | 2 | 2019 | 561 | 0.190 |
Why?
|
| Boronic Acids | 1 | 2005 | 915 | 0.180 |
Why?
|
| Eye Diseases | 1 | 2006 | 653 | 0.180 |
Why?
|
| Proteome | 1 | 2010 | 1856 | 0.180 |
Why?
|
| Child | 27 | 2019 | 80154 | 0.180 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2019 | 4021 | 0.170 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2013 | 4052 | 0.170 |
Why?
|
| Nephrectomy | 2 | 2015 | 938 | 0.170 |
Why?
|
| Magnetic Resonance Imaging | 14 | 2017 | 36415 | 0.170 |
Why?
|
| Treatment Failure | 6 | 2017 | 2643 | 0.170 |
Why?
|
| Thoracic Wall | 2 | 2013 | 202 | 0.170 |
Why?
|
| Pyrazines | 1 | 2005 | 1202 | 0.160 |
Why?
|
| Arm | 2 | 2013 | 589 | 0.160 |
Why?
|
| Bile Duct Neoplasms | 2 | 2015 | 607 | 0.160 |
Why?
|
| Disease Management | 2 | 2021 | 2507 | 0.160 |
Why?
|
| Breast Neoplasms | 11 | 2020 | 20982 | 0.160 |
Why?
|
| Dacarbazine | 4 | 2012 | 559 | 0.160 |
Why?
|
| Neoplasm Proteins | 1 | 2010 | 3594 | 0.150 |
Why?
|
| Abdominal Fat | 1 | 2020 | 221 | 0.150 |
Why?
|
| Gastrointestinal Stromal Tumors | 2 | 2014 | 617 | 0.150 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 2017 | 39 | 0.150 |
Why?
|
| Child, Preschool | 16 | 2019 | 42225 | 0.150 |
Why?
|
| Radiometry | 4 | 2013 | 812 | 0.150 |
Why?
|
| Deoxycytidine | 2 | 2014 | 878 | 0.150 |
Why?
|
| Medulloblastoma | 2 | 2017 | 677 | 0.140 |
Why?
|
| Radiography | 7 | 2015 | 6974 | 0.140 |
Why?
|
| Losartan | 1 | 2019 | 263 | 0.140 |
Why?
|
| Solitary Fibrous Tumors | 1 | 2018 | 67 | 0.140 |
Why?
|
| Prospective Studies | 18 | 2019 | 54437 | 0.140 |
Why?
|
| Peritoneal Neoplasms | 3 | 1993 | 710 | 0.140 |
Why?
|
| Neuroectodermal Tumors, Primitive | 2 | 1995 | 136 | 0.140 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2005 | 915 | 0.140 |
Why?
|
| Proteomics | 1 | 2010 | 3840 | 0.140 |
Why?
|
| Liver Failure | 1 | 2019 | 250 | 0.140 |
Why?
|
| Time Factors | 16 | 2019 | 39957 | 0.130 |
Why?
|
| Radiation Tolerance | 4 | 2015 | 478 | 0.130 |
Why?
|
| Sarcoma, Alveolar Soft Part | 1 | 2016 | 43 | 0.130 |
Why?
|
| Postoperative Complications | 8 | 2018 | 15637 | 0.130 |
Why?
|
| Cell Dedifferentiation | 1 | 2016 | 122 | 0.130 |
Why?
|
| Ireland | 2 | 2013 | 169 | 0.120 |
Why?
|
| Pleural Neoplasms | 4 | 1994 | 609 | 0.120 |
Why?
|
| Intestine, Small | 4 | 2017 | 1207 | 0.120 |
Why?
|
| Algorithms | 8 | 2023 | 14025 | 0.120 |
Why?
|
| Sacrococcygeal Region | 1 | 2014 | 53 | 0.120 |
Why?
|
| Th2 Cells | 4 | 2001 | 1071 | 0.120 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 3 | 2001 | 897 | 0.120 |
Why?
|
| Radiation, Ionizing | 1 | 2015 | 252 | 0.120 |
Why?
|
| Liposarcoma, Myxoid | 2 | 2014 | 60 | 0.110 |
Why?
|
| Pyrimidines | 3 | 2018 | 3027 | 0.110 |
Why?
|
| Nose Neoplasms | 1 | 2016 | 249 | 0.110 |
Why?
|
| Linear Energy Transfer | 3 | 2017 | 151 | 0.110 |
Why?
|
| Pain, Intractable | 1 | 1994 | 132 | 0.110 |
Why?
|
| Pelvic Neoplasms | 1 | 2015 | 247 | 0.110 |
Why?
|
| Skin Neoplasms | 4 | 2007 | 5809 | 0.110 |
Why?
|
| Databases, Factual | 4 | 2017 | 7965 | 0.110 |
Why?
|
| Perfusion Imaging | 1 | 2015 | 198 | 0.110 |
Why?
|
| Fibromatosis, Abdominal | 1 | 2012 | 21 | 0.100 |
Why?
|
| Myxosarcoma | 1 | 2012 | 11 | 0.100 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2013 | 54 | 0.100 |
Why?
|
| Analysis of Variance | 3 | 2009 | 6223 | 0.100 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2017 | 592 | 0.100 |
Why?
|
| Proportional Hazards Models | 9 | 2019 | 12474 | 0.100 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2014 | 368 | 0.100 |
Why?
|
| Mastocytosis | 1 | 1994 | 150 | 0.100 |
Why?
|
| Observer Variation | 3 | 2015 | 2610 | 0.100 |
Why?
|
| Sarcoma, Synovial | 2 | 2014 | 153 | 0.100 |
Why?
|
| Preoperative Period | 2 | 2012 | 551 | 0.100 |
Why?
|
| Cerebellar Neoplasms | 1 | 2017 | 586 | 0.100 |
Why?
|
| Hepatectomy | 1 | 2015 | 557 | 0.100 |
Why?
|
| Endpoint Determination | 1 | 2014 | 590 | 0.090 |
Why?
|
| Antineoplastic Agents | 8 | 2015 | 13632 | 0.090 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2015 | 620 | 0.090 |
Why?
|
| Professional Staff Committees | 2 | 2001 | 37 | 0.090 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2014 | 1726 | 0.090 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2012 | 677 | 0.090 |
Why?
|
| Bone Diseases | 1 | 1994 | 418 | 0.090 |
Why?
|
| Lung Neoplasms | 6 | 2020 | 13386 | 0.090 |
Why?
|
| Asymptomatic Diseases | 1 | 2013 | 588 | 0.090 |
Why?
|
| Bone Density | 1 | 2023 | 3546 | 0.090 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2016 | 1111 | 0.090 |
Why?
|
| Medical Illustration | 1 | 2011 | 135 | 0.090 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2014 | 646 | 0.090 |
Why?
|
| Pilot Projects | 4 | 2023 | 8642 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2014 | 726 | 0.090 |
Why?
|
| Foot | 1 | 1994 | 575 | 0.090 |
Why?
|
| Terminology as Topic | 2 | 2014 | 1528 | 0.090 |
Why?
|
| Radiation Dosage | 5 | 2017 | 1962 | 0.080 |
Why?
|
| Thigh | 1 | 2011 | 239 | 0.080 |
Why?
|
| Esophageal Neoplasms | 1 | 2020 | 1658 | 0.080 |
Why?
|
| Perioperative Care | 1 | 2017 | 1037 | 0.080 |
Why?
|
| Intraoperative Care | 5 | 2017 | 767 | 0.080 |
Why?
|
| Biopsy | 1 | 2021 | 6781 | 0.080 |
Why?
|
| Cell Proliferation | 3 | 2016 | 10423 | 0.080 |
Why?
|
| Immunoconjugates | 3 | 2001 | 963 | 0.080 |
Why?
|
| Edema | 1 | 2013 | 764 | 0.080 |
Why?
|
| Hand | 1 | 1994 | 902 | 0.080 |
Why?
|
| Spinal Fractures | 1 | 2015 | 704 | 0.080 |
Why?
|
| Adenocarcinoma | 4 | 2018 | 6341 | 0.080 |
Why?
|
| Photosensitizing Agents | 1 | 1993 | 625 | 0.080 |
Why?
|
| Th1 Cells | 4 | 2001 | 1042 | 0.080 |
Why?
|
| Sarcoma, Clear Cell | 1 | 2009 | 72 | 0.080 |
Why?
|
| Perception | 1 | 2015 | 1198 | 0.080 |
Why?
|
| Quality of Life | 5 | 2021 | 13367 | 0.080 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 1549 | 0.080 |
Why?
|
| Lower Extremity | 2 | 2013 | 1201 | 0.080 |
Why?
|
| Brain Neoplasms | 6 | 2014 | 9025 | 0.080 |
Why?
|
| Mastectomy | 2 | 2013 | 1818 | 0.080 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2018 | 1393 | 0.080 |
Why?
|
| beta Catenin | 1 | 2013 | 1042 | 0.080 |
Why?
|
| Drug Information Services | 1 | 2008 | 51 | 0.080 |
Why?
|
| Furans | 1 | 2009 | 201 | 0.070 |
Why?
|
| Massachusetts | 3 | 2010 | 8837 | 0.070 |
Why?
|
| Wound Healing | 2 | 2012 | 2800 | 0.070 |
Why?
|
| Mitomycin | 2 | 2019 | 263 | 0.070 |
Why?
|
| Neurosurgical Procedures | 1 | 2018 | 2067 | 0.070 |
Why?
|
| Chondromatosis, Synovial | 1 | 2007 | 17 | 0.070 |
Why?
|
| Multiple Myeloma | 1 | 2005 | 5145 | 0.070 |
Why?
|
| Imidazoles | 2 | 2004 | 1172 | 0.070 |
Why?
|
| Lymphangiosarcoma | 1 | 2006 | 14 | 0.070 |
Why?
|
| Gastrointestinal Diseases | 1 | 2015 | 1201 | 0.070 |
Why?
|
| Alkyl and Aryl Transferases | 2 | 2004 | 86 | 0.070 |
Why?
|
| Diagnostic Imaging | 1 | 2021 | 3534 | 0.070 |
Why?
|
| Respiration | 1 | 2013 | 1657 | 0.070 |
Why?
|
| Lung | 6 | 2006 | 9979 | 0.070 |
Why?
|
| Regression Analysis | 1 | 2016 | 6345 | 0.070 |
Why?
|
| Osteolysis, Essential | 1 | 2006 | 30 | 0.070 |
Why?
|
| Muscle Neoplasms | 1 | 2008 | 130 | 0.070 |
Why?
|
| Facility Design and Construction | 1 | 2007 | 85 | 0.070 |
Why?
|
| Research Design | 3 | 2014 | 6180 | 0.070 |
Why?
|
| Radiation-Protective Agents | 3 | 1992 | 88 | 0.070 |
Why?
|
| Carbon | 1 | 2010 | 665 | 0.070 |
Why?
|
| Microvessels | 1 | 2010 | 580 | 0.070 |
Why?
|
| Vascular Neoplasms | 1 | 2008 | 166 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 5 | 2009 | 6125 | 0.060 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2006 | 782 | 0.060 |
Why?
|
| Leiomyosarcoma | 1 | 2010 | 422 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2016 | 2915 | 0.060 |
Why?
|
| Lymphatic Metastasis | 2 | 2013 | 2913 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2006 | 254 | 0.060 |
Why?
|
| Phototherapy | 2 | 2004 | 368 | 0.060 |
Why?
|
| Patient Admission | 1 | 2013 | 1365 | 0.060 |
Why?
|
| Disease Progression | 6 | 2019 | 13511 | 0.060 |
Why?
|
| Radiation Pneumonitis | 2 | 2018 | 102 | 0.060 |
Why?
|
| Fingers | 1 | 2008 | 506 | 0.060 |
Why?
|
| Glioma | 3 | 1995 | 3452 | 0.060 |
Why?
|
| Risk Factors | 9 | 2020 | 74241 | 0.060 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2009 | 732 | 0.060 |
Why?
|
| Endometrial Neoplasms | 1 | 2013 | 1366 | 0.060 |
Why?
|
| Fractures, Bone | 2 | 2013 | 2046 | 0.060 |
Why?
|
| Age Factors | 6 | 2017 | 18384 | 0.060 |
Why?
|
| Patient Care Team | 1 | 2015 | 2515 | 0.060 |
Why?
|
| Skull Neoplasms | 1 | 2005 | 173 | 0.060 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2008 | 858 | 0.060 |
Why?
|
| Cause of Death | 3 | 2019 | 3688 | 0.060 |
Why?
|
| Acclimatization | 1 | 1984 | 113 | 0.050 |
Why?
|
| MicroRNAs | 1 | 2019 | 3758 | 0.050 |
Why?
|
| Equipment Design | 2 | 2007 | 3510 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2018 | 5321 | 0.050 |
Why?
|
| Internal Fixators | 1 | 2004 | 184 | 0.050 |
Why?
|
| Carcinoma | 2 | 2004 | 2330 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 5493 | 0.050 |
Why?
|
| North America | 2 | 2018 | 1284 | 0.050 |
Why?
|
| Ilium | 1 | 2023 | 154 | 0.050 |
Why?
|
| Iodine Radioisotopes | 1 | 1986 | 1030 | 0.050 |
Why?
|
| Kidney Failure, Chronic | 1 | 2015 | 2478 | 0.050 |
Why?
|
| Hemangioma | 1 | 2008 | 727 | 0.050 |
Why?
|
| Idoxuridine | 2 | 1993 | 111 | 0.050 |
Why?
|
| T-Lymphocytes | 3 | 2018 | 10203 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2018 | 4642 | 0.050 |
Why?
|
| Protein Kinases | 1 | 2009 | 1607 | 0.050 |
Why?
|
| Respiratory Hypersensitivity | 2 | 2001 | 271 | 0.050 |
Why?
|
| Patient Selection | 2 | 2012 | 4246 | 0.050 |
Why?
|
| Pentobarbital | 3 | 1992 | 153 | 0.050 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2017 | 3610 | 0.050 |
Why?
|
| SEER Program | 2 | 2017 | 1453 | 0.050 |
Why?
|
| Documentation | 1 | 2008 | 900 | 0.050 |
Why?
|
| Neoplasm Metastasis | 2 | 2018 | 4909 | 0.050 |
Why?
|
| Europe | 2 | 2018 | 3423 | 0.050 |
Why?
|
| Hematoma | 1 | 2006 | 763 | 0.050 |
Why?
|
| United States | 7 | 2017 | 72341 | 0.050 |
Why?
|
| Prostatic Neoplasms | 3 | 2010 | 11101 | 0.050 |
Why?
|
| Cancer Care Facilities | 1 | 2004 | 422 | 0.050 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 2254 | 0.050 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2006 | 1118 | 0.050 |
Why?
|
| Clinical Trials as Topic | 5 | 2008 | 8002 | 0.050 |
Why?
|
| Continuity of Patient Care | 1 | 2008 | 1069 | 0.050 |
Why?
|
| Health Care Rationing | 1 | 2004 | 435 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2013 | 3923 | 0.040 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2006 | 557 | 0.040 |
Why?
|
| Acute Disease | 2 | 2015 | 7226 | 0.040 |
Why?
|
| Radiation | 1 | 2020 | 49 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2006 | 1664 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2009 | 2455 | 0.040 |
Why?
|
| Infant | 7 | 2018 | 36170 | 0.040 |
Why?
|
| Shoulder Joint | 1 | 2007 | 742 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 4014 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 1986 | 1270 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2021 | 41496 | 0.040 |
Why?
|
| Hematoporphyrins | 3 | 1989 | 23 | 0.040 |
Why?
|
| Receptors, Chemokine | 2 | 2001 | 654 | 0.040 |
Why?
|
| Respiratory Mucosa | 2 | 2001 | 436 | 0.040 |
Why?
|
| Immunity, Mucosal | 2 | 2001 | 485 | 0.040 |
Why?
|
| Bronchial Hyperreactivity | 1 | 2001 | 301 | 0.040 |
Why?
|
| Interleukin-3 | 1 | 2001 | 425 | 0.040 |
Why?
|
| Clinical Competence | 1 | 2015 | 4788 | 0.040 |
Why?
|
| Disability Evaluation | 2 | 2017 | 1834 | 0.040 |
Why?
|
| Risk | 4 | 2018 | 9616 | 0.040 |
Why?
|
| Bone Transplantation | 1 | 2004 | 923 | 0.040 |
Why?
|
| Infection Control | 1 | 2006 | 983 | 0.040 |
Why?
|
| Colostomy | 1 | 2019 | 105 | 0.040 |
Why?
|
| Research | 1 | 2007 | 1976 | 0.040 |
Why?
|
| Animals | 18 | 2018 | 168089 | 0.040 |
Why?
|
| Mitotic Index | 2 | 2016 | 162 | 0.040 |
Why?
|
| Pancreaticoduodenectomy | 2 | 2014 | 509 | 0.040 |
Why?
|
| Chemokines, CXC | 1 | 2000 | 416 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2008 | 1668 | 0.040 |
Why?
|
| Receptors, Interleukin-1 | 1 | 1999 | 262 | 0.040 |
Why?
|
| Hematoporphyrin Derivative | 2 | 1988 | 10 | 0.040 |
Why?
|
| Cross-Sectional Studies | 3 | 2017 | 26072 | 0.040 |
Why?
|
| Muscles | 1 | 2023 | 1568 | 0.040 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2018 | 50 | 0.040 |
Why?
|
| Palliative Care | 3 | 2007 | 3599 | 0.040 |
Why?
|
| Contrast Media | 1 | 2011 | 5311 | 0.040 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 2017 | 58 | 0.040 |
Why?
|
| Hemoglobin A | 1 | 1997 | 84 | 0.040 |
Why?
|
| Recombinant Proteins | 2 | 1998 | 6504 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2007 | 2820 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2014 | 10218 | 0.040 |
Why?
|
| Leucovorin | 1 | 2019 | 643 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 6 | 2001 | 6200 | 0.040 |
Why?
|
| Hot Temperature | 1 | 1984 | 1434 | 0.040 |
Why?
|
| Stomach | 2 | 2015 | 697 | 0.040 |
Why?
|
| Pyridines | 1 | 2009 | 2872 | 0.040 |
Why?
|
| Lymphocyte Subsets | 1 | 2018 | 312 | 0.030 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2018 | 307 | 0.030 |
Why?
|
| Lymphoma, B-Cell | 1 | 2003 | 938 | 0.030 |
Why?
|
| Ovarian Neoplasms | 2 | 1993 | 4872 | 0.030 |
Why?
|
| Tumor Stem Cell Assay | 1 | 1996 | 115 | 0.030 |
Why?
|
| Anal Canal | 1 | 2019 | 374 | 0.030 |
Why?
|
| Infusions, Intravenous | 3 | 2004 | 2217 | 0.030 |
Why?
|
| Orgasm | 1 | 2016 | 62 | 0.030 |
Why?
|
| Karnofsky Performance Status | 1 | 2016 | 166 | 0.030 |
Why?
|
| Mitochondrial Size | 1 | 2015 | 8 | 0.030 |
Why?
|
| Lymphatic Irradiation | 1 | 2016 | 115 | 0.030 |
Why?
|
| Electrons | 1 | 2017 | 265 | 0.030 |
Why?
|
| Genital Neoplasms, Female | 1 | 2001 | 533 | 0.030 |
Why?
|
| Mutation | 3 | 2017 | 30004 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2003 | 1985 | 0.030 |
Why?
|
| Receptors, CXCR4 | 1 | 2000 | 727 | 0.030 |
Why?
|
| Vermont | 1 | 2015 | 81 | 0.030 |
Why?
|
| Urinary Bladder Diseases | 1 | 1996 | 167 | 0.030 |
Why?
|
| Cell Survival | 3 | 2002 | 5778 | 0.030 |
Why?
|
| Adjuvants, Immunologic | 1 | 2001 | 988 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2011 | 20118 | 0.030 |
Why?
|
| Growth Plate | 1 | 2017 | 275 | 0.030 |
Why?
|
| Peritoneal Cavity | 1 | 2015 | 135 | 0.030 |
Why?
|
| Survivors | 2 | 2014 | 2369 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2008 | 3441 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 9417 | 0.030 |
Why?
|
| Spinal Fusion | 1 | 2004 | 1294 | 0.030 |
Why?
|
| Surgical Wound Infection | 2 | 2022 | 1530 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2007 | 14675 | 0.030 |
Why?
|
| Frameshift Mutation | 1 | 2016 | 392 | 0.030 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 1 | 1994 | 42 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2007 | 3366 | 0.030 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 1 | 1994 | 43 | 0.030 |
Why?
|
| Receptors, CXCR | 1 | 2014 | 52 | 0.030 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 12052 | 0.030 |
Why?
|
| Mastectomy, Radical | 1 | 1993 | 19 | 0.030 |
Why?
|
| CA-19-9 Antigen | 1 | 2014 | 106 | 0.030 |
Why?
|
| Mastectomy, Simple | 1 | 1993 | 23 | 0.030 |
Why?
|
| Models, Biological | 1 | 2010 | 9458 | 0.030 |
Why?
|
| Perioperative Period | 1 | 2015 | 252 | 0.030 |
Why?
|
| Cell Division | 2 | 1996 | 4451 | 0.030 |
Why?
|
| Mastectomy, Modified Radical | 1 | 1993 | 62 | 0.030 |
Why?
|
| Antigens, Differentiation | 3 | 2001 | 918 | 0.030 |
Why?
|
| Farnesyltranstransferase | 2 | 2004 | 71 | 0.030 |
Why?
|
| Skull Base | 1 | 2016 | 292 | 0.030 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2003 | 1405 | 0.030 |
Why?
|
| Femoral Neoplasms | 1 | 1993 | 84 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2015 | 680 | 0.030 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2014 | 335 | 0.030 |
Why?
|
| Heart | 1 | 2006 | 4431 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2009 | 5665 | 0.030 |
Why?
|
| Leukocytes | 1 | 2001 | 2025 | 0.030 |
Why?
|
| Cyclophosphamide | 2 | 1996 | 2219 | 0.030 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2014 | 270 | 0.030 |
Why?
|
| Incidence | 4 | 2019 | 21366 | 0.030 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2013 | 297 | 0.030 |
Why?
|
| Pleura | 1 | 1994 | 244 | 0.030 |
Why?
|
| Giant Cells | 1 | 2012 | 188 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2003 | 2223 | 0.020 |
Why?
|
| Radiation Injuries, Experimental | 1 | 1992 | 88 | 0.020 |
Why?
|
| Mobility Limitation | 1 | 2016 | 408 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2017 | 2928 | 0.020 |
Why?
|
| Duodenum | 1 | 2015 | 491 | 0.020 |
Why?
|
| Thymidine | 1 | 1992 | 296 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2016 | 1217 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2018 | 4373 | 0.020 |
Why?
|
| Barbiturates | 1 | 1992 | 113 | 0.020 |
Why?
|
| Urinary Incontinence | 1 | 2016 | 490 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2020 | 2024 | 0.020 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1995 | 890 | 0.020 |
Why?
|
| Radioisotopes | 1 | 2013 | 502 | 0.020 |
Why?
|
| Genes, ras | 1 | 2014 | 654 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2017 | 1256 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2016 | 2277 | 0.020 |
Why?
|
| Mesothelioma | 3 | 1994 | 807 | 0.020 |
Why?
|
| Mastectomy, Segmental | 2 | 2006 | 955 | 0.020 |
Why?
|
| Mice | 11 | 2015 | 81330 | 0.020 |
Why?
|
| Receptors, CCR3 | 2 | 2001 | 62 | 0.020 |
Why?
|
| Genotype | 2 | 2017 | 12985 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 1997 | 1264 | 0.020 |
Why?
|
| Body Composition | 1 | 2020 | 2427 | 0.020 |
Why?
|
| Esophagus | 1 | 2017 | 1036 | 0.020 |
Why?
|
| Rare Diseases | 1 | 2016 | 624 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2018 | 4574 | 0.020 |
Why?
|
| Receptors, CCR4 | 2 | 2001 | 77 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2015 | 1602 | 0.020 |
Why?
|
| Delphi Technique | 1 | 2014 | 848 | 0.020 |
Why?
|
| Drug Administration Schedule | 2 | 1996 | 4851 | 0.020 |
Why?
|
| Fast Neutrons | 1 | 2010 | 18 | 0.020 |
Why?
|
| Carboplatin | 1 | 2013 | 793 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2015 | 1818 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2016 | 2509 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2004 | 10756 | 0.020 |
Why?
|
| Thyroid Gland | 1 | 2017 | 1169 | 0.020 |
Why?
|
| Apoptosis | 2 | 2009 | 9478 | 0.020 |
Why?
|
| Necrosis | 1 | 2014 | 1610 | 0.020 |
Why?
|
| Decision Trees | 1 | 1992 | 505 | 0.020 |
Why?
|
| Photography | 1 | 2013 | 532 | 0.020 |
Why?
|
| Fiber Optic Technology | 1 | 1991 | 290 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2018 | 2329 | 0.020 |
Why?
|
| Creatinine | 1 | 2015 | 1897 | 0.020 |
Why?
|
| Technology, Radiologic | 1 | 2010 | 160 | 0.020 |
Why?
|
| Anastomosis, Surgical | 1 | 1993 | 982 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 2018 | 2194 | 0.020 |
Why?
|
| ras Proteins | 1 | 2014 | 1055 | 0.020 |
Why?
|
| Bronchial Neoplasms | 1 | 1989 | 110 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2016 | 2658 | 0.020 |
Why?
|
| Reoperation | 2 | 2004 | 4303 | 0.020 |
Why?
|
| Benzamides | 1 | 2014 | 1371 | 0.020 |
Why?
|
| Laser Therapy | 2 | 1993 | 1094 | 0.020 |
Why?
|
| Mitral Valve Stenosis | 1 | 1990 | 341 | 0.020 |
Why?
|
| Ovalbumin | 2 | 2000 | 671 | 0.020 |
Why?
|
| Random Allocation | 1 | 1993 | 2393 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 1992 | 793 | 0.020 |
Why?
|
| Cytarabine | 1 | 2010 | 697 | 0.020 |
Why?
|
| Hospital Records | 1 | 2008 | 93 | 0.020 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2015 | 943 | 0.020 |
Why?
|
| Gadolinium | 1 | 2013 | 961 | 0.020 |
Why?
|
| Pyrroles | 1 | 2014 | 1124 | 0.020 |
Why?
|
| Photochemistry | 1 | 1988 | 238 | 0.020 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 1997 | 2223 | 0.020 |
Why?
|
| Prescriptions | 1 | 2010 | 386 | 0.020 |
Why?
|
| Calcinosis | 1 | 1996 | 1477 | 0.020 |
Why?
|
| Melanoma | 1 | 2006 | 5694 | 0.020 |
Why?
|
| Kidney | 2 | 2017 | 7033 | 0.020 |
Why?
|
| Upper Extremity | 1 | 2012 | 658 | 0.020 |
Why?
|
| Liver | 2 | 2017 | 7512 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2020 | 22174 | 0.020 |
Why?
|
| Colon | 1 | 2015 | 1791 | 0.020 |
Why?
|
| Heart Neoplasms | 1 | 1990 | 364 | 0.020 |
Why?
|
| Pain, Postoperative | 1 | 2017 | 1741 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2015 | 2182 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 1992 | 1743 | 0.020 |
Why?
|
| Telangiectasis | 1 | 2006 | 78 | 0.020 |
Why?
|
| Rabbits | 1 | 1993 | 4750 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2023 | 8998 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 1746 | 0.020 |
Why?
|
| Shoulder Pain | 1 | 2007 | 151 | 0.020 |
Why?
|
| Antigens, CD | 3 | 2001 | 4009 | 0.020 |
Why?
|
| Chylothorax | 1 | 2006 | 83 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2015 | 4111 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2013 | 1730 | 0.020 |
Why?
|
| Indoles | 1 | 2014 | 1830 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 1992 | 1436 | 0.020 |
Why?
|
| Eosinophilia | 2 | 2001 | 557 | 0.020 |
Why?
|
| Cytokines | 4 | 2001 | 7386 | 0.020 |
Why?
|
| Fatigue | 1 | 2013 | 1550 | 0.020 |
Why?
|
| Scapula | 1 | 2007 | 173 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2016 | 3549 | 0.020 |
Why?
|
| Rats, Inbred F344 | 3 | 1992 | 826 | 0.020 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1989 | 749 | 0.020 |
Why?
|
| Rats | 5 | 2001 | 23705 | 0.020 |
Why?
|
| Esthetics | 1 | 2006 | 327 | 0.010 |
Why?
|
| Immunoglobulin E | 2 | 2001 | 1505 | 0.010 |
Why?
|
| Vagotomy | 1 | 1984 | 83 | 0.010 |
Why?
|
| Proteins | 1 | 1999 | 5993 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2008 | 1150 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2015 | 2636 | 0.010 |
Why?
|
| Sinoatrial Node | 1 | 1984 | 99 | 0.010 |
Why?
|
| Subtraction Technique | 1 | 2007 | 518 | 0.010 |
Why?
|
| Bone Marrow | 1 | 1994 | 2911 | 0.010 |
Why?
|
| Cell Line, Tumor | 2 | 2015 | 16954 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1988 | 2263 | 0.010 |
Why?
|
| Medical Staff, Hospital | 1 | 2008 | 601 | 0.010 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 3634 | 0.010 |
Why?
|
| Sex Factors | 1 | 2017 | 10553 | 0.010 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 1990 | 1139 | 0.010 |
Why?
|
| Piperazines | 1 | 2014 | 2522 | 0.010 |
Why?
|
| Gene Expression | 3 | 2001 | 7571 | 0.010 |
Why?
|
| Braces | 1 | 2004 | 139 | 0.010 |
Why?
|
| Genes, bcl-2 | 1 | 2003 | 119 | 0.010 |
Why?
|
| Bronchoscopy | 1 | 1989 | 909 | 0.010 |
Why?
|
| Signal Transduction | 3 | 2001 | 23419 | 0.010 |
Why?
|
| Cisplatin | 1 | 2009 | 1652 | 0.010 |
Why?
|
| Mammaplasty | 1 | 2013 | 1232 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 1988 | 1225 | 0.010 |
Why?
|
| Bradycardia | 1 | 1984 | 298 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 1999 | 7851 | 0.010 |
Why?
|
| Stomach Neoplasms | 1 | 1993 | 1457 | 0.010 |
Why?
|
| Anxiety | 1 | 2017 | 4569 | 0.010 |
Why?
|
| Rectum | 1 | 2007 | 891 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2008 | 15521 | 0.010 |
Why?
|
| Recurrence | 2 | 2007 | 8457 | 0.010 |
Why?
|
| Carcinoma, Lobular | 1 | 2006 | 480 | 0.010 |
Why?
|
| Cricetulus | 1 | 1984 | 812 | 0.010 |
Why?
|
| Pelvis | 1 | 1986 | 735 | 0.010 |
Why?
|
| Allergens | 2 | 2000 | 1433 | 0.010 |
Why?
|
| Medication Errors | 1 | 2008 | 783 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2006 | 1838 | 0.010 |
Why?
|
| Risk Assessment | 3 | 2010 | 24022 | 0.010 |
Why?
|
| Mitochondria | 1 | 2015 | 3620 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 4513 | 0.010 |
Why?
|
| Receptors, CCR8 | 1 | 2001 | 28 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2009 | 5032 | 0.010 |
Why?
|
| Forecasting | 2 | 2001 | 2928 | 0.010 |
Why?
|
| Mental Health | 1 | 2016 | 3251 | 0.010 |
Why?
|
| Rats, Inbred WKY | 1 | 2001 | 150 | 0.010 |
Why?
|
| Health Personnel | 1 | 2015 | 3337 | 0.010 |
Why?
|
| Cell Line | 3 | 2000 | 15545 | 0.010 |
Why?
|
| Clonal Deletion | 1 | 2001 | 74 | 0.010 |
Why?
|
| Immunohistochemistry | 2 | 2006 | 11067 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2014 | 3537 | 0.010 |
Why?
|
| Urinary Bladder | 1 | 2007 | 1152 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2008 | 2425 | 0.010 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2003 | 646 | 0.010 |
Why?
|
| Germinal Center | 1 | 2003 | 380 | 0.010 |
Why?
|
| Pulmonary Artery | 1 | 1989 | 1929 | 0.010 |
Why?
|
| Parents | 1 | 2014 | 3564 | 0.010 |
Why?
|
| Clonal Anergy | 1 | 2001 | 169 | 0.010 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2000 | 340 | 0.010 |
Why?
|
| Cricetinae | 1 | 1984 | 2412 | 0.010 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2009 | 2058 | 0.010 |
Why?
|
| Immune Sera | 1 | 2000 | 605 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2009 | 2864 | 0.010 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2001 | 955 | 0.010 |
Why?
|
| Stomatitis | 1 | 2002 | 271 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 2018 | 26200 | 0.010 |
Why?
|
| Neutralization Tests | 1 | 2001 | 725 | 0.010 |
Why?
|
| Mouth Mucosa | 1 | 2002 | 432 | 0.010 |
Why?
|
| Ovary | 1 | 1984 | 957 | 0.010 |
Why?
|
| Lymphocyte Activation | 2 | 2001 | 5478 | 0.010 |
Why?
|
| Enterotoxins | 1 | 2001 | 365 | 0.010 |
Why?
|
| Nausea | 1 | 2002 | 678 | 0.010 |
Why?
|
| Smoking | 1 | 2016 | 9055 | 0.010 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2006 | 1084 | 0.010 |
Why?
|
| Organizational Objectives | 1 | 2001 | 426 | 0.010 |
Why?
|
| Vomiting | 1 | 2002 | 650 | 0.010 |
Why?
|
| Jurkat Cells | 1 | 2000 | 739 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 8531 | 0.010 |
Why?
|
| Administration, Intranasal | 1 | 2000 | 476 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2001 | 1376 | 0.010 |
Why?
|
| Cell Movement | 2 | 2001 | 5195 | 0.010 |
Why?
|
| Receptors, Interleukin | 1 | 1999 | 242 | 0.010 |
Why?
|
| Gene Rearrangement | 1 | 2003 | 1125 | 0.010 |
Why?
|
| Chemokine CXCL12 | 1 | 2000 | 454 | 0.010 |
Why?
|
| Hematologic Diseases | 1 | 2002 | 496 | 0.010 |
Why?
|
| COS Cells | 1 | 1999 | 1129 | 0.010 |
Why?
|
| Breast | 1 | 2006 | 1964 | 0.010 |
Why?
|
| Mice, Transgenic | 2 | 2000 | 9520 | 0.010 |
Why?
|
| Depression | 1 | 2017 | 8132 | 0.010 |
Why?
|
| Adoptive Transfer | 1 | 2000 | 823 | 0.010 |
Why?
|
| Intraoperative Complications | 1 | 2004 | 1164 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2001 | 800 | 0.010 |
Why?
|
| Research Support as Topic | 1 | 2001 | 697 | 0.010 |
Why?
|
| Prevalence | 1 | 2013 | 15721 | 0.010 |
Why?
|
| Length of Stay | 1 | 2010 | 6417 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2008 | 4420 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2004 | 4822 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 2000 | 1527 | 0.010 |
Why?
|
| Antigens, Bacterial | 1 | 2001 | 1140 | 0.010 |
Why?
|
| Crystallization | 1 | 1996 | 528 | 0.010 |
Why?
|
| Etoposide | 1 | 1996 | 635 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2000 | 4167 | 0.010 |
Why?
|
| Interleukins | 1 | 1999 | 782 | 0.010 |
Why?
|
| Cells, Cultured | 2 | 2001 | 18927 | 0.010 |
Why?
|
| Disease Models, Animal | 3 | 2001 | 18222 | 0.010 |
Why?
|
| Cell Differentiation | 2 | 2003 | 11512 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2006 | 3453 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2003 | 6067 | 0.010 |
Why?
|
| Vincristine | 1 | 1996 | 1036 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 2 | 2001 | 9187 | 0.010 |
Why?
|
| Skin Diseases | 1 | 2002 | 1095 | 0.010 |
Why?
|
| Brain | 2 | 1990 | 27094 | 0.010 |
Why?
|
| Kinetics | 1 | 2001 | 6312 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1993 | 372 | 0.010 |
Why?
|
| Methohexital | 1 | 1992 | 17 | 0.010 |
Why?
|
| Staphylococcus aureus | 1 | 2001 | 1450 | 0.010 |
Why?
|
| Thiopental | 1 | 1992 | 55 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 2 | 2001 | 22128 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2000 | 2603 | 0.010 |
Why?
|
| Medical Audit | 1 | 1993 | 452 | 0.010 |
Why?
|
| Thoracotomy | 1 | 1994 | 366 | 0.010 |
Why?
|
| Transfection | 1 | 1999 | 5748 | 0.010 |
Why?
|
| Phenobarbital | 1 | 1992 | 191 | 0.010 |
Why?
|
| Pseudomyxoma Peritonei | 1 | 1991 | 21 | 0.010 |
Why?
|
| Boston | 1 | 2004 | 9327 | 0.010 |
Why?
|
| Neutropenia | 1 | 1996 | 885 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 1999 | 3155 | 0.010 |
Why?
|
| HIV Infections | 1 | 1997 | 17348 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1999 | 3726 | 0.010 |
Why?
|
| Monocytes | 1 | 2000 | 2570 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 1992 | 914 | 0.010 |
Why?
|
| Carcinoma in Situ | 1 | 1996 | 791 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 1999 | 2802 | 0.010 |
Why?
|
| Diazepam | 1 | 1990 | 215 | 0.010 |
Why?
|
| Contracture | 1 | 1991 | 235 | 0.010 |
Why?
|
| Dogs | 1 | 1994 | 3832 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 2000 | 13402 | 0.000 |
Why?
|
| Hypothermia | 1 | 1990 | 188 | 0.000 |
Why?
|
| Thrombocytopenia | 1 | 1996 | 1182 | 0.000 |
Why?
|
| Immunoglobulin G | 1 | 2000 | 4537 | 0.000 |
Why?
|
| Gastrectomy | 1 | 1993 | 672 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 2000 | 17598 | 0.000 |
Why?
|
| Health Services Accessibility | 1 | 2004 | 5426 | 0.000 |
Why?
|
| Receptors, GABA-A | 1 | 1990 | 621 | 0.000 |
Why?
|
| Mice, Knockout | 1 | 2001 | 14392 | 0.000 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1991 | 732 | 0.000 |
Why?
|
| Drug Resistance | 1 | 1991 | 1594 | 0.000 |
Why?
|
| Atropine | 1 | 1984 | 244 | 0.000 |
Why?
|
| Anesthesia, General | 1 | 1990 | 1174 | 0.000 |
Why?
|
| Vagus Nerve | 1 | 1984 | 458 | 0.000 |
Why?
|
| Flow Cytometry | 1 | 1992 | 5871 | 0.000 |
Why?
|
| Inflammation | 1 | 2001 | 10759 | 0.000 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1990 | 3770 | 0.000 |
Why?
|
| Skin | 1 | 1991 | 4473 | 0.000 |
Why?
|
| Myocardium | 1 | 1990 | 4746 | 0.000 |
Why?
|
| Heart Failure | 1 | 1996 | 11701 | 0.000 |
Why?
|